Impact of single nucleotide polymorphisms and of clinical risk factors on new-onset diabetes mellitus in HIV-infected individuals

Rotger, Margalida; Gsponer, Thomas; Martinez, Raquel; Taffé, Patrick; Elzi, Luigia; Vernazza, Pietro; Cavassini, Matthias; Bernasconi, Enos; Hirschel, Bernard; Furrer, Hansjakob; Weber, Rainer; Ledergerber, Bruno; Egger, Matthias; Telenti, Amalio; Tarr, Philip E (2010). Impact of single nucleotide polymorphisms and of clinical risk factors on new-onset diabetes mellitus in HIV-infected individuals. Clinical infectious diseases, 51(9), pp. 1090-1098. Cary, N.C.: The University of Chicago Press 10.1086/656630

[img] Text
Rotger ClinInfectDis 2010.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (448kB) | Request a copy
[img]
Preview
Text
51-9-1090.pdf - Other
Available under License Publisher holds Copyright.

Download (898kB) | Preview

Background. Metabolic complications, including cardiovascular events and diabetes mellitus (DM), are a major long-term concern in human immunodeficienc virus (HIV)-infected individuals. Recent genome-wide association studies have reliably associated multiple single nucleotide polymorphisms (SNPs) to DM in the general population. Methods. We evaluated the contribution of 22 SNPs identifie in genome-wide association studies and of longitudinally measured clinical factors to DM. We genotyped all 94 white participants in the Swiss HIV Cohort Study who developed DM from 1 January 1999 through 31 August 2009 and 550 participants without DM. Analyses were based on 6054 person-years of follow-up and 13,922 measurements of plasma glucose. Results. The contribution to DM risk explained by SNPs (14% of DM variability) was larger than the contribution to DM risk explained by current or cumulative exposure to different antiretroviral therapy combinations (3% of DM variability). Participants with the most unfavorable genetic score (representing 12% and 19% of the study population, respectively, when applying 2 different genetic scores) had incidence rate ratios for DM of 3.80 (95% confidenc interval [CI], 2.05–7.06) and 2.74 (95% CI, 1.53–4.88), respectively, compared with participants with a favorable genetic score. However, addition of genetic data to clinical risk factors that included body mass index only slightly improved DM prediction. Conclusions. In white HIV-infected persons treated with antiretroviral therapy, the DM effect of genetic variants was larger than the potential toxic effects of antiretroviral therapy. SNPs contributed significantl to DM risk, but their addition to a clinical model improved DM prediction only slightly, similar to studies in the general population.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Gsponer, Thomas; Furrer, Hansjakob and Egger, Matthias

ISSN:

1058-4838

Publisher:

The University of Chicago Press

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:09

Last Modified:

27 Apr 2018 08:41

Publisher DOI:

10.1086/656630

PubMed ID:

20879858

Web of Science ID:

000283331300017

BORIS DOI:

10.7892/boris.1140

URI:

https://boris.unibe.ch/id/eprint/1140 (FactScience: 201946)

Actions (login required)

Edit item Edit item
Provide Feedback